

BrainCool AB (publ): BrainCool receives a patent approval for "shivering" in the EU for the product BrainCool™ System

The final step for patent protection of the BrainCool™ System has been completed with the approval of our technology to manage shivering during cooling in the EU. The patent for addressing 'shivering' has already been approved in the USA, Sweden, Japan, South Korea, and China.

CEO Martin Waleij comments:

- "It is a clear and significant indication of the level of technology and degree of innovation of the product, which ensures its special position as a leading 'high-quality TTM system' globally.

Our patented product, the BrainCool™ System, is designed to accommodate various treatment strategies, target temperatures, and indications. The system has the capability to achieve rapid and strong cooling effects, and its patented features offer significant advantages over competing products."

Contacts

For more information

Martin Waleij - CEO

+46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

About Us

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Oncology. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named "BRAIN".

Eminova Fondkommission AB is the company's Certified Adviser.

Attachments

[BrainCool AB \(publ\): BrainCool receives a patent approval for "shivering" in the EU for the product BrainCool™ System](#)